GLP (Good Laboratory Practice) and GMP (Good Manufacturing Practice) are two quality systems that govern different stages of bringing a pharmaceutical product to market. GLP covers the research and testing phase, ensuring that safety data from lab studies is reliable. GMP covers the manufacturing phase, ensuring that every batch of a product is made consistently and meets quality standards. Together, they form the regulatory backbone that protects consumers from unsafe or poorly made drugs, medical devices, and other regulated products.
What GLP Covers
Good Laboratory Practice is a set of rules for how non-clinical laboratory studies must be conducted. These are the safety studies that happen before a drug ever reaches human trials: toxicology tests, pharmacology studies, and biocompatibility assessments. The goal is to make sure the data coming out of these studies is trustworthy and reproducible. If a lab finds that a compound is safe at a certain dose, regulators need confidence that the finding is real, not the result of sloppy procedures or contaminated samples.
In the United States, GLP is codified in 21 CFR Part 58, enforced by the FDA. The regulations spell out requirements across several areas. Every person involved in a study must have appropriate education, training, and experience. Testing facilities must be properly sized and constructed, with separate areas for biohazardous materials like radioactive substances or infectious agents. All equipment used to generate or measure data must be tested, calibrated, and standardized.
One distinctive feature of GLP is the Study Director role. This single person holds ultimate responsibility for the conduct of a study, its compliance with regulations, and the integrity of its data. That kind of singular accountability doesn’t exist in the same way under GMP, which distributes responsibility more broadly across production teams.
What GMP Covers
Good Manufacturing Practice kicks in once a product moves from the lab to the factory floor. According to the World Health Organization, GMP is a system for ensuring that products are consistently produced and controlled according to quality standards. It exists because you can’t guarantee a drug’s safety just by testing the final product. By the time a pill is packaged, any number of things could have gone wrong during production, from contaminated equipment to mislabeled ingredients. GMP requires systems that provide documented proof that correct procedures were followed at every step, every time a product is made.
In the U.S., GMP for finished pharmaceuticals falls under 21 CFR Parts 210 and 211. These regulations require a quality control unit with the authority to approve or reject components, packaging materials, labeling, and finished products. Written procedures must be in place for every production and process control step, designed to ensure that each drug has the identity, strength, quality, and purity it’s supposed to have. Buildings need adequate space to prevent mix-ups between different components. Equipment must be cleaned, maintained, and sanitized at appropriate intervals. Before any batch is released, lab testing must confirm it meets final specifications, including the identity and strength of each active ingredient.
Process validation is a core GMP concept. It means demonstrating, with a high degree of assurance, that a manufacturing process consistently produces a product meeting all its intended attributes. This includes qualifying utilities and equipment by verifying they were built to design specifications and operate correctly across all anticipated conditions.
How GLP and GMP Differ
The simplest way to understand the difference: GLP protects the integrity of data, while GMP protects the quality of products. GLP asks, “Can we trust what this study found?” GMP asks, “Was this batch made correctly?”
That core distinction shapes how each system handles quality oversight. Under GLP, a Quality Assurance Unit focuses on process. It conducts audits to verify that studies are being run according to protocol and that data is being recorded properly. Under GMP, a Quality Control Unit focuses on the product itself, running tests and validating manufacturing processes to confirm that what comes off the production line is safe and consistent.
Documentation standards also differ in purpose. GLP demands extensive records so that a study can be traced and, in principle, reproduced. Every observation, every deviation, every calibration record feeds into a final study report that regulators review when deciding whether a drug is safe enough for human testing. GMP documentation, by contrast, centers on manufacturing records. Batch records, equipment logs, and deviation reports exist to prove that each production run followed approved procedures and to enable targeted recalls if something goes wrong after a product reaches the market.
International Standards
Both GLP and GMP have international frameworks that allow countries to recognize each other’s data and inspections, which is critical for a global pharmaceutical supply chain.
For GLP, the Organisation for Economic Co-operation and Development (OECD) established a set of principles that most countries follow. These cover ten areas: test facility organization and personnel, quality assurance programs, facilities, apparatus and reagents, test systems, test and reference items, standard operating procedures, study performance, reporting of results, and storage of records and materials. When a study is conducted under OECD GLP principles in one member country, other member countries accept the data without requiring the study to be repeated. This saves time, money, and animal lives.
For GMP, the WHO published its first guidelines in 1969 as part of a certification scheme for pharmaceutical products moving in international commerce. More than 100 countries have since incorporated WHO GMP provisions into their national medicines laws, and many others have used the WHO framework as a starting point for their own requirements. The WHO GMP also serves as the basis for prequalification of vaccines purchased by UN agencies, making it a practical gatekeeper for global health programs. A supplementary annex adopted in 1991 extends GMP principles to biological products like vaccines, blood products, cell therapies, and biopharmaceuticals.
Where They Overlap
Despite their different focuses, GLP and GMP share common ground. Both require trained, qualified personnel. Both mandate that facilities be designed to prevent contamination. Both insist on calibrated, well-maintained equipment. Both demand thorough documentation and record-keeping. And both exist for the same underlying reason: to build a verifiable chain of trust from the earliest safety study through to the finished product a patient takes home.
In practice, many pharmaceutical and biotech companies maintain compliance with both systems simultaneously, since their operations span research and manufacturing. A contract research organization running preclinical safety studies operates under GLP. A contract manufacturer producing drug products operates under GMP. A large integrated company may need both, plus Good Clinical Practice (GCP) for its human trials, forming the trio of “GxP” standards that regulators expect throughout a product’s lifecycle.
What Happens When Companies Fall Short
Regulatory agencies enforce GLP and GMP through facility inspections. When inspectors find violations, they issue observations (known in the U.S. as FDA Form 483s). If problems are serious or go uncorrected, the FDA can escalate to warning letters, which become public record and can damage a company’s reputation, delay product approvals, or halt manufacturing altogether. In extreme cases, products may be seized or facilities shut down.
The consequences extend beyond direct enforcement. A GLP violation can invalidate an entire safety study, potentially setting a drug development program back months or years. A GMP violation can force a product recall affecting thousands of patients. For companies operating in regulated industries, maintaining compliance with these systems isn’t just a legal obligation. It’s the cost of doing business in a market where regulators, healthcare providers, and patients all depend on the same chain of documented quality.